Epidermal growth factor is a potential biomarker for poor cetuximab response in tongue cancer cells. (Q27853131)

EGF mutant receptor vIII as a molecular target in cancer therapy

21 January 2018

1 reference

The EGF receptor family as targets for cancer therapy

21 January 2018

1 reference

Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs

21 January 2018

1 reference

Untangling the ErbB signalling network

21 January 2018

1 reference

A comprehensive pathway map of epidermal growth factor receptor signaling

21 January 2018

1 reference

Structural basis for inhibition of the epidermal growth factor receptor by cetuximab

21 January 2018

1 reference

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

21 January 2018

1 reference

Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer

21 January 2018

1 reference

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

21 January 2018

1 reference

Mutations, expression and genomic instability of the H-ras proto-oncogene in squamous cell carcinomas of the head and neck

21 January 2018

1 reference

21 January 2018

1 reference

Role of the EGFR ligand/receptor system in the secretion of angiogenic factors in mesenchymal stem cells

21 January 2018

1 reference

Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells

21 January 2018

1 reference

Amphiregulin promotes resistance to gefitinib in nonsmall cell lung cancer cells by regulating Ku70 acetylation

21 January 2018

1 reference

Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients

21 January 2018

1 reference

Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment

21 January 2018

1 reference

Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma

21 January 2018

1 reference

Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab

21 January 2018

1 reference

Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers

21 January 2018

1 reference

Autocrine epidermal growth factor receptor ligand production and cetuximab response in head and neck squamous cell carcinoma cell lines

21 January 2018

1 reference

EGFR status and EGFR ligand expression influence the treatment response of head and neck cancer cell lines.

21 January 2018

1 reference

Quantitative real-time PCR for the measurement of feline cytokine mRNA.

21 January 2018

1 reference

Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies

21 January 2018

1 reference

Amphiregulin promotes BAX inhibition and resistance to gefitinib in non-small-cell lung cancers.

21 January 2018

1 reference

Differential effects of EGFR ligands on endocytic sorting of the receptor.

21 January 2018

1 reference

Immunohistochemical localization of epidermal growth factor (EGF) and EGF receptor in human oral mucosa and its malignancy

21 January 2018

1 reference

Cancer-associated fibroblasts induce matrix metalloproteinase-mediated cetuximab resistance in head and neck squamous cell carcinoma cells

21 January 2018

1 reference